Vir Biotechnology price to sales ratio VIR

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 5.9×
6-year median: 15.6×
Against its 6-year history: 25th; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.2× to 129×
Peer median: 6.8×

Vir Biotechnology's price to sales ratio is 5.9× as of Oct 23, 2026.

That is below its 6-year median of 15.6×, lower than on 75% of days in the last 6 years.

Over that time it ranged from 1.2× in Sep 2022 to 129× in Feb 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.9×	4.9×	62.4×
2025	49.5×	10.2×	55.2×
2024	13.1×	9.8×	19.2×
2023	11.4×	1.3×	11.4×
2022	1.4×	1.2×	17.8×
2021	19.3×	14.4×	129×
2020	45.1×	45.1×	89.4×

Against its peers

Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.

Company	Price to sales ratio
VIRVir Biotechnology	5.9×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
MGTXMeiraGTx	2.2×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
PLXProtalix BioTherapeutics	2.5×
EXELExelixis	6.6×
Peer median	6.8×

Where Vir Biotechnology ranks

#28of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vir Biotechnology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.